Man Group’s Clearside Biomedical CLSD Stock Holding History

Man Group’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-9,727	Closed	-$897K	–	1940
2018 Q3	$897K	Sell	9,727 -114	-1%	-$13.6K	﹤0.01%	1705
2018 Q2	$1.58M	Buy	+9,841	New	+$1.66M	0.01%	1458

Other funds holding CLSD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's CLSD Position: Q4 2018 in Review

Man Group sold out of Clearside Biomedical (CLSD) in Q4 2018, closing a stake of 9,727 shares — an estimated $897K sold.

Man Group first reported a position in CLSD in Q2 2018 and held it in 2 quarters. The position peaked at $1.58M in Q2 2018. 69 funds tracked by Wall St. Rank hold CLSD as of Q4 2018.

Man Group reported no remaining Clearside Biomedical position as of Q4 2018 after selling out during the quarter.
Man Group sold 9,727 Clearside Biomedical shares in Q4 2018, an estimated $897K.
Man Group first reported a position in Clearside Biomedical in Q2 2018 and held it in 2 quarters.
Man Group's Clearside Biomedical position peaked at $1.58M in Q2 2018.
69 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2018.

Based on Man Group's 13F filing for Q4 2018, filed 14 Feb 2019.